Back to top
more

Curis (CRIS)

(Delayed Data from NSDQ)

$14.53 USD

14.53
1,704

+0.01 (0.07%)

Updated Apr 26, 2024 10:13 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CRIS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Curis, Inc. [CRIS]

Reports for Purchase

Showing records 121 - 140 ( 302 total )

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

12/10/2013

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

12/10/2013

Daily Note

Pages: 5

ASH 2013 - Interim CUDC-907 Data in 11 Patients Preliminary - Too Early To Tell - 2014 Catalysts Ahead - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

12/10/2013

Daily Note

Pages: 5

ASH 2013 - Interim CUDC-907 Data in 11 Patients Preliminary

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

12/09/2013

Company Report

Pages: 8

Early Responses for ''907; Dose and Schedule Search Ongoing

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

12/08/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

12/08/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

12/05/2013

Company Report

Pages: 26

Initiating with OUTPERFORM and $6 Price Target: Early Stage Candidates Offer a Targeted Path to Value Creation Supported by Growing Erivedge Sales

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 75.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

11/06/2013

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

11/06/2013

Company Report

Pages: 8

Hopefully a Temporary Glitch; Removing from Focus List; Maintain Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

10/17/2013

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

10/17/2013

Daily Note

Pages: 4

Nice Erivedge Trajectory Continues; Important Data in March 2014

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

10/04/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

10/04/2013

Daily Note

Pages: 7

R&D Day Summary; Pipeline Visibility Increasing as Expected; Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

08/06/2013

Daily Note

Pages: 12

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

08/05/2013

Daily Note

Pages: 6

2Q13 Results; All Programs Continue to Build; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

07/26/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

07/25/2013

Daily Note

Pages: 8

CUDC-427 Moves Forward as Expected; Erivedge Revenue Trends Continue

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

07/15/2013

Daily Note

Pages: 4

E.U. Approval for Erivedge; $6 M to CRIS; Story Keeps Building

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

07/15/2013

Daily Note

Pages: 2

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

06/11/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party